FDA RECALLS & COURT ACTIONS: May 26, 1993
CLASS II UPDATE - Diazepam Injection, USP 5 mg/ml, and Cyanocobalamin Injection, 1,000 mcg/ml, Recall number: D-208/209-3, Manufacturer: Steris Laboratories, which appeared in the April 14, 1993 "Enforcement Report" ("The Pink Sheet" April 19, T&G-14) involves products distributed under the H. L. Moore label only. CLASS III - BULK GUAIFENENSIN USP In 50 or 50.6 kg fiber drums. Recall number: D-268-3. Lot numbers range between 22766 and 30921. Manufacturer: B.I. Chemical Corporation, Petersburg, Virginia. Recalled by: Manufacturer, by letter April 16 and 26, 1993. Firm-initiated recall ongoing. Distribution: Midwest and east coast; 157,063 kg were distributed Reason: Presence of aluminum particles.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth